Quantcast

Latest Tyrosine kinase inhibitors Stories

2014-07-17 16:26:09

NEW YORK, July 17, 2014 /PRNewswire/ -- Exelixis, Inc. (Nasdaq: EXEL) is a development stage biotech company. EXEL developed two cancer treatments cabozantinib (Cabo, Cometriq) and cobimetinib (Cobi). Both use small molecules as the active component. The company has a partnership with Roche to commercialize, market and distribute cobi. Cobi is expected to earn approval in the treatment of melanoma by late 2015, after positive phase-three trial results earlier this week. Cabo is...

2014-05-15 08:31:37

ROCKVILLE, Md., May 15, 2014 /PRNewswire/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and other diseases, today reported financial results for the three months ended March 31, 2014. http://photos.prnewswire.com/prnvar/20010620/ENMDLOGO The Company reported a net loss for the first quarter of 2014 of ($1.5 million), or ($0.05) per share, compared with a net loss of ($1.1 million), or ($0.05) per share,...

2014-02-24 08:29:21

SOUTH SAN FRANCISCO, Calif., Feb. 24, 2014 /PRNewswire/ -- Calithera Biosciences, Inc., a clinical-stage biopharmaceutical company discovering and developing novel small molecule therapeutics in cancer, today announced the commencement of patient dosing in its first Phase 1 study of CB-839 in patients with advanced solid tumors. CB-839 is a potent, selective, orally bioavailable inhibitor of glutaminase that interferes with tumor metabolism and blocks cancer cell growth and...


Word of the Day
lambent
  • Licking.
  • Hence Running along or over a surface, as if in the act of licking; flowing over or along; lapping or bathing; softly bright; gleaming.
This word comes the Latin 'lambere,' to lick.
Related